Tacrolimus exposure during the three-month period following allogeneic stem cell transplantation predicts overall survival

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10498448" target="_blank" >RIV/00179906:_____/25:10498448 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/25:10498448 RIV/00216208:11150/25:10498448 RIV/00216208:11160/25:10498448 RIV/00064165:_____/25:10498448

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.j~xsvvqGJ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.j~xsvvqGJ</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fphar.2025.1517083" target="_blank" >10.3389/fphar.2025.1517083</a>

Result language

angličtina

Original language name

Tacrolimus exposure during the three-month period following allogeneic stem cell transplantation predicts overall survival

Original language description

Objectives: The objective of this study was to investigate the relationship between both short-term and long-term tacrolimus exposure and overall survival after allogeneic stem cell transplantation and to propose individualized tacrolimus dosing based on the population pharmacokinetic model. Study design: Tacrolimus exposure during the first 3 months of therapy after transplantation was calculated using therapeutic drug monitoring data from all patients who underwent allogeneic stem cell transplantation from 2016 to 2018. The optimal upper level was determined using ROC analysis, and the impact of cutoff tacrolimus exposure values on overall survival of patients was assessed together with other transplant variables using multivariate analysis. The population pharmacokinetic model was developed using a nonlinear mixed-effects modeling method, and the optimal tacrolimus dose was proposed. Results: A total of 86 patients were included in the outcome analyses. Except for the disease risk category, age &gt;= 55 years, and female-to-male donor, tacrolimus exposures of the area under the curve of trough concentrations (AUC(tc)) &gt;= 222 ng h/mL, &gt;= 258 ng h/mL, and &gt;= 160 ng h/mL during the whole three-month period, second month, and third month of therapy, respectively, were also found to be statistically significant for overall survival in univariate analysis. These AUC(tc) values were independent variables for overall survival in multivariate analysis, with RR of 3.01 (P = 0.0056), 3.22 (P = 0.0058), and 2.93 (P = 0.0184) for the whole three-month period, second month, and third month of therapy, respectively. The disease risk category (RR 7.11; P &lt; 0.0001), age (RR 2.45; P = 0.0214), and non-myeloablative conditioning (RR 3.39; P = 0.0014) were also significant factors influencing survival in multivariate analysis. Tacrolimus volume of distribution was 127.1 L and was not affected by any of the tested covariates, whereas clearance decreased with age according to the equation CL=7.94xe(-0.0085xage ) and was reduced by 23% in patients who underwent repeat transplantation. Conclusion: Except for the disease risk category, age, and non-myeloablative conditioning, exposure to tacrolimus is an independent predictor of overall survival and should not exceed trough levels of 10.7 ng/mL during the second month and 6.8 ng/mL during third month after transplantation. In order to reach this target, nomogram for estimation of the maximal initial tacrolimus daily dose was developed based on the population pharmacokinetic model.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

<a href="/en/project/NU23-03-00562" target="_blank" >NU23-03-00562: Development of resistance mechanisms to FLT3 inhibitors; role of bone marrow microenvironment</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Pharmacology

ISSN

1663-9812

e-ISSN

1663-9812

Volume of the periodical

16

Issue of the periodical within the volume

April

Country of publishing house

CH - SWITZERLAND

Number of pages

11

Pages from-to

1517083

UT code for WoS article

001483978200001

EID of the result in the Scopus database

2-s2.0-105004462698